```html

Klebsiella pneumoniae Carbapenem‑Resistant Infection

Overview

Klebsiella pneumoniae is a gram‑negative rod‑shaped bacterium that normally lives in the intestines, skin, and respiratory tract of healthy people. In some circumstances it can cause serious infections such as pneumonia, urinary‑tract infections (UTIs), bloodstream infections, and intra‑abdominal infections. When the organism acquires resistance to carbapenems—broad‑spectrum antibiotics that are often considered the “last‑line” treatment—it becomes a **carbapenem‑resistant Klebsiella pneumoniae (CRKP)** infection. CRKP is classified as a “critical priority” pathogen by the World Health Organization because it is difficult to treat and associated with high mortality rates.

Who it affects

• Hospitalized patients, especially those in intensive care units (ICUs)
• Individuals with invasive devices (ventilators, central lines, urinary catheters)
• People who have received broad‑spectrum antibiotics in the past 3 months
• Patients with weakened immune systems (e.g., chemotherapy, organ transplant, HIV)
• Long‑term care facility residents

Prevalence

• In the United States, the CDC estimates ~13,000 cases of carbapenem‑resistant Enterobacteriaceae (CRE) annually, 50–60 % of which involve Klebsiella pneumoniae.<sup>1</sup>
• European surveillance (EARS‑Net, 2022) reported a median prevalence of 0.5 % among invasive Klebsiella isolates, with some countries >1 %.<sup>2</sup>
• Mortality rates range from 30 % to 70 % depending on infection site and timeliness of effective therapy.<sup>3</sup>

Symptoms

The clinical picture depends on the infection site. Below is a consolidated list of the most common symptoms, grouped by organ system.

Respiratory (Pneumonia)

• Fever and chills
• Cough with thick, sometimes blood‑tinged sputum
• Shortness of breath or rapid breathing
• Chest pain that worsens with deep breaths
• Fatigue and confusion, especially in older adults

Urinary Tract

• Burning sensation during urination
• Frequent urge to urinate, often with small volumes
• Cloudy, foul‑smelling, or blood‑stained urine
• Lower abdominal or back pain
• Fever, sometimes with chills

Bloodstream (Bacteremia/Sepsis)

• High fever (≥38.3 °C / 101 °F) or hypothermia
• Rapid heart rate (tachycardia) and low blood pressure
• Confusion, altered mental status
• Generalized weakness or malaise
• Skin mottling or rash

Intra‑abdominal (e.g., intra‑abdominal abscess, peritonitis)

• Severe abdominal pain or tenderness
• Distended abdomen, guarding, or rigidity
• Nausea, vomiting, loss of appetite
• Fever and chills

Skin & Soft Tissue

• Red, swollen, painful area at the site of a wound or catheter
• Purulent (pus‑filled) drainage
• Fever or chills if infection spreads

Causes and Risk Factors

CRKP infections arise when a normally harmless Klebsiella strain picks up genes that produce carbapenem‑hydrolyzing enzymes (carbapenemases). The most common enzymes are KPC (Klebsiella pneumoniae carbapenemase), NDM (New Delhi metallo‑β‑lactamase), OXA‑48‑like, and VIM.

How resistance spreads

• Plasmids: Mobile DNA fragments that can transfer between bacteria, spreading carbapenemase genes rapidly.
• Healthcare environment: Contaminated surfaces, equipment, and hands of healthcare workers act as vectors.
• Antibiotic pressure: Overuse of broad‑spectrum antibiotics selects for resistant strains.

Risk factors

• Recent hospitalization (especially >5 days)
• ICU stay or mechanical ventilation
• Presence of central venous catheters, urinary catheters, or feeding tubes
• Previous treatment with carbapenems, cephalosporins, or fluoroquinolones
• Immunosuppression (e.g., corticosteroids, chemotherapy, transplant medications)
• Chronic lung disease, diabetes, or chronic kidney disease
• Living in or recent transfer from a long‑term care facility with known CRE outbreaks

Diagnosis

Early and accurate diagnosis is essential because delayed effective therapy worsens outcomes.

Clinical evaluation

• Detailed history (hospital exposures, antibiotic use, device presence)
• Physical examination focused on infection site

Laboratory & microbiology

• Specimen collection: Blood, sputum, urine, wound swab, or tissue biopsy obtained using sterile technique.
• Culture: Grows Klebsiella pneumoniae on standard media within 24‑48 hours.
• Antimicrobial susceptibility testing (AST): Automated systems (VITEK 2, BD Phoenix) or disk diffusion determine carbapenem MICs. A minimum inhibitory concentration (MIC) ≥4 µg/mL for meropenem or imipenem usually indicates resistance.
• Carbapenemase detection:
  • Phenotypic tests (e.g., Modified Hodge Test, Carba NP)
  • Molecular PCR assays targeting bla_KPC, bla_NDM, bla_OXA‑48, etc.
• Whole‑genome sequencing (in reference labs) can trace outbreak strains and resistance genes.

Imaging (as indicated)

• Chest X‑ray or CT scan for pneumonia
• Abdominal CT for intra‑abdominal infections
• Ultrasound for renal or biliary involvement

Treatment Options

Because CRKP is resistant to carbapenems, therapy relies on newer or combination agents, often guided by susceptibility results and local antibiograms.

First‑line antimicrobial regimens (as of 2024)

1. Cefiderocol (Fetroja) – a siderophore cephalosporin active against many carbapenem‑resistant organisms. Dose: 2 g IV every 8 h (adjust for renal function).<sup>4</sup>
2. Ceftazidime‑avibactam (Avycaz) plus aztreonam – useful for KPC‑producing strains; aztreonam covers metallo‑β‑lactamases (NDM, VIM).<sup>5</sup>
3. Meropenem‑vaborbactam (Vabomere) – approved for KPC‑producing CRE; dose 4 g IV q8h.
4. Plazomicin – an aminoglycoside with activity against many CRE; monitor drug levels and kidney function.

Combination therapy

• Polymyxins (colistin or polymyxin B) + carbapenem or tigecycline may be used when susceptibilities are limited, but nephrotoxicity and neurotoxicity are concerns.<sup>6</sup>
• Dual therapy (e.g., ceftazidime‑avibactam + aztreonam) is increasingly recommended for NDM‑producing CRKP.

Adjunctive measures

• Source control: Removal or replacement of infected catheters, drainage of abscesses, surgical debridement when indicated.
• Supportive care: Intravenous fluids, vasopressors for septic shock, oxygen or mechanical ventilation for respiratory failure.
• Infection control in hospitals: Contact precautions, daily chlorhexidine bathing, environmental cleaning.

Lifestyle & supportive strategies

• Maintain adequate hydration and nutrition to support immune function.
• Adhere strictly to prescribed medication schedules; never stop antibiotics early.
• Report any new fevers, worsening pain, or changes in wound drainage promptly.

Living with Klebsiella pneumoniae Carbapenem‑Resistant Infection

Even after the acute infection resolves, patients may need ongoing vigilance.

• Follow‑up appointments: Repeat cultures may be required to confirm eradication, especially for bloodstream infections.
• Medication adherence: Some regimens last 7‑14 days (or longer for deep‑seat infections). Use pill organizers or alarms.
• Device care: If you retain a urinary catheter, central line, or feeding tube, learn aseptic handling techniques from your care team.
• Nutrition: High‑protein, vitamin‑rich diet helps tissue repair. Consult a dietitian if you have appetite loss.
• Physical activity: Light activity as tolerated improves circulation and lung function; avoid strenuous exercise until cleared.
• Mental health: Chronic infection can be stressful. Seek counseling, support groups, or mindfulness practices.

Prevention

Because CRKP spreads primarily in healthcare settings, prevention focuses on both institutional practices and personal habits.

In healthcare facilities

• Strict hand hygiene – alcohol‑based rubs or soap and water before and after patient contact.
• Contact precautions (gown and gloves) for patients known or suspected to carry CRE.
• Active surveillance cultures in high‑risk units (ICU, transplant wards).
• Environmental cleaning with EPA‑registered disinfectants effective against gram‑negative bacteria.
• Antimicrobial stewardship programs to limit unnecessary carbapenem use.

For patients and families

• Ask healthcare providers about the necessity of indwelling devices; request removal as soon as possible.
• Ensure that visitors practice hand hygiene before entering the room.
• If you have been discharged with a wound or catheter, follow the home‑care instructions meticulously.
• Vaccinations (influenza, pneumococcal) reduce the chance of secondary infections that could require antibiotics.
• Maintain a healthy lifestyle—balanced diet, regular exercise, adequate sleep—to support immune defenses.

Complications

If CRKP infection is not promptly and adequately treated, several serious complications can develop.

• Septic shock – profound hypotension requiring vasopressors; carries a mortality >40 %.
• Acute respiratory distress syndrome (ARDS) from severe pneumonia.
• Renal failure – either from sepsis or nephrotoxic antibiotics (e.g., polymyxins).
• End‑organ damage – heart (myocarditis), brain (meningitis), or liver dysfunction.
• Chronic colonization – some patients become long‑term carriers, increasing future infection risk and facilitating spread.
• Metastatic infections – bacteria can seed distant sites, leading to osteomyelitis, endocarditis, or prosthetic joint infection.

When to Seek Emergency Care

---

Sources: 1. CDC. “Antibiotic Resistance Threats in the United States, 2019.” 2. European Centre for Disease Prevention and Control (ECDC). “Surveillance of Antimicrobial Resistance in Europe 2022.” 3. Lee, R. et al. “Clinical Outcomes of Carbapenem‑Resistant Klebsiella pneumoniae Infections.” Clin Infect Dis. 2021. 4. FDA. “Cefiderocol (Fetroja) Prescribing Information,” 2023. 5. FDA. “Ceftazidime‑Avibactam and Aztreonam for Metallo‑β‑lactamase‑producing CRE,” 2022. 6. van Duin, D. & Kothe, K. “Management of Carbapenem‑Resistant Enterobacteriaceae Infections.” Clin Microbiol Rev. 2020. Additional guidance from Mayo Clinic, Cleveland Clinic, and WHO.

```